Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

In vivo genome editing restores hemostasis in mouse model of blood clotting disorder

Using an innovative gene therapy technique called genome editing that hones in on the precise location of mutated DNA, scientists have treated the blood clotting disorder hemophilia in mice.

27 Jun 2011

New model of health care delivery relies on active participation of patients and caregivers

A new model of care developed for patients at the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences (UAMS) has led to improved patient experience, lower costs and better patient outcomes.

24 Jun 2011

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Baxter International Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.

From Baxter International Inc. 24 Jun 2011

Potential new approach for treating myelofibrosis

A new study conducted by a team of researchers at Boston University School of Medicine (BUSM) sheds light on a possible new approach to treat the bone marrow disease known as myelofibrosis by inhibiting an enzyme that connects extracellular fibers.

24 Jun 2011

New genetic research holds promise for patients with Chuvash polycythemia

New research conducted at UNC Lineberger Comprehensive Cancer Center, offers hope for people with a rare disorder called Chuvash polycythemia.

23 Jun 2011

Experts to focus on Shwachman-Diamond Syndrome at New York Academy of Sciences conference

On June 28-30, 2011, the New York Academy of Sciences will bring together scientists and clinicians from a wide range of subspecialties, in addition to patients and caregivers, to discuss the most important recent advances in our understanding of the clinical features, management, and treatment of Shwachman-Diamond Syndrome (SDS)-a rare disorder involving multiple organ systems and affecting children and young adults.

23 Jun 2011

Nine young clinical investigators earn recognition from Damon Runyon Cancer Research Foundation

The Damon Runyon Cancer Research Foundation named five new Damon Runyon Clinical Investigators at its spring 2011 Clinical Investigator Award Committee review.

22 Jun 2011

EpiCept announces results of 2011 stockholders annual meeting

EpiCept Corporation announced today the results of its 2011 Annual Meeting of Stockholders held on June 14, 2011.

20 Jun 2011

PDA urges public to undergo screening for oral cancer

Oral cancer claims more lives than leukemia, Hodgkin's lymphoma, laryngeal cancer, testicular cancer, thyroid cancer, or skin cancer. In 2010, approximately 36,540 Americans were diagnosed with this largely preventable type of cancer that affects the mouth and throat; 7,880 died of the disease. Early detection is essential to dramatically reduce the number of deaths from oral cancer.

18 Jun 2011

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene International Sàrl announced that clinical data from a Phase II study, conducted by investigators from the MD Anderson Cancer Center in Houston, TX, evaluating the combination regimen of REVLIMID plus rituximab (R2) in untreated, advanced stage, indolent B-cell non-Hodgkin's lymphomas, were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

18 Jun 2011

CBAI acquires assets of NeoCells for $320,000

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, is pleased to announce that it has acquired the assets of NeoCells, a subsidiary of ViviCells International, Inc., Evanston, Illinois, through a foreclosure procedure at a purchase price of $320,000.

17 Jun 2011

Placental growth factor also plays a role in chronic myeloid leukemia

Chronic myeloid leukemia (CML) is a particular form of leukemia or cancer of the bone marrow, which can be treated with targeted imatinib. However, in some cases this medicine has no effect. Researchers at the VIB Vesalius Research Centre, K.U. Leuven, under the direction of Peter Carmeliet, have investigated the role of placental growth factor (PlGF) in mice with CML.

15 Jun 2011

QIAGEN to acquire Ipsogen

QIAGEN N.V. has made an offer and entered into exclusive negotiations to purchase a 47% initial stake in Ipsogen S.A. and subsequently make a public offer to fully acquire a global leader in molecular profiling and personalized healthcare diagnostics for a broad range of hematological cancers.

From QIAGEN Manchester Limited 15 Jun 2011

Researchers investigate the role of PlGF in mice with chronic myeloid leukemia

14 Jun 2011

JEM published paper identifies new gene mutations in patients with chronic lymphocytic leukemia

A paper published online on June 13 in the Journal of Experimental Medicine identifies new gene mutations in patients with chronic lymphocytic leukemia (CLL)—a disease often associated with lack of response to chemotherapy and poor overall survival.

14 Jun 2011

Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML

Ambit Biosciences Corporation and Astellas Pharma Inc. announced today results from a planned interim analysis in an ongoing Phase 2 study evaluating AC220, a potent and selective FLT3 inhibitor.

14 Jun 2011

Formaldehyde & other chemicals declared carcinogenic: Report

The government, last Friday added formaldehyde, a substance found in plastics and other commonly used products, to a list of known carcinogens and warned that the chemical styrene might cause cancer.

13 Jun 2011

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.

13 Jun 2011

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two ongoing Phase I studies with MLN9708, the first oral proteasome inhibitor being studied in patients with relapsed and/or refractory multiple myeloma.

13 Jun 2011

HHS adds eight substances to 12th Report on Carcinogens

The U.S. Department of Health and Human Services added eight substances to its Report on Carcinogens, a science-based document that identifies chemicals and biological agents that may put people at increased risk for cancer.

13 Jun 2011

Leukemia News and Research

Further Reading

In vivo genome editing restores hemostasis in mouse model of blood clotting disorder

New model of health care delivery relies on active participation of patients and caregivers

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Potential new approach for treating myelofibrosis

New genetic research holds promise for patients with Chuvash polycythemia

Experts to focus on Shwachman-Diamond Syndrome at New York Academy of Sciences conference

Nine young clinical investigators earn recognition from Damon Runyon Cancer Research Foundation

EpiCept announces results of 2011 stockholders annual meeting

PDA urges public to undergo screening for oral cancer

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

CBAI acquires assets of NeoCells for $320,000

Placental growth factor also plays a role in chronic myeloid leukemia

QIAGEN to acquire Ipsogen

Researchers investigate the role of PlGF in mice with chronic myeloid leukemia

JEM published paper identifies new gene mutations in patients with chronic lymphocytic leukemia

Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML

Formaldehyde & other chemicals declared carcinogenic: Report

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

HHS adds eight substances to 12th Report on Carcinogens

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News